Primary Biliary Cirrhosis Pipeline Review, H1 2019 - ResearchAndMarkets.com

The "Primary
Biliary Cirrhosis - Pipeline Review, H1 2019" drug pipelines
has been added to ResearchAndMarkets.com's offering.

Primary Biliary Cirrhosis - Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also
reviews of key players involved in therapeutic development for Primary
Biliary Cirrhosis and features dormant and discontinued projects. The
guide covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III, Phase
II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 11, 3,
1, 2 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Primary Biliary Cirrhosis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Primary Biliary
  Cirrhosis (Gastrointestinal) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Primary Biliary
  Cirrhosis (Gastrointestinal) therapeutics and enlists all their major
  and minor projects.
• The pipeline guide evaluates Primary Biliary Cirrhosis
  (Gastrointestinal) therapeutics based on mechanism of action (MoA),
  drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

Companies Mentioned

• Albireo Pharma Inc
• Allergan Plc
• Arena Pharmaceuticals Inc
• Biocad
• Cadila Healthcare Ltd
• CymaBay Therapeutics Inc
• Dr. Falk Pharma GmbH
• Eli Lilly and Co
• Enanta Pharmaceuticals Inc
• Genfit SA
• GenKyoTex SA
• Gilead Sciences Inc
• Kowa Co Ltd
• NGM Biopharmaceuticals Inc
• Novartis AG
• Tiziana Life Sciences Plc
• Virobay Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gndih8

View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005695/en/